BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Siponimod (Mayzent) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Siponimod (Mayzent)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06639282-7389@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Siponimod (Mayzent): Phase 2 readout est. (NCT06639282)
DESCRIPTION:Siponimod (Mayzent)\, phase 2.\nStudy: Repurposing Siponimod fo
 r Alzheimer's Disease\nEstimated primary completion: October 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/siponimod-mayzent#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06639282
URL:https://assetmemo.bio/drug/siponimod-mayzent#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00162474-7389@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Siponimod (Mayzent): Phase na readout est. (NCT00162474)
DESCRIPTION:Siponimod (Mayzent)\, phase na.\nStudy: Determinants of Warfari
 n Metabolism\nEstimated primary completion: December 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/siponimod-mayzent#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT00162474
URL:https://assetmemo.bio/drug/siponimod-mayzent#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
